Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alpha Tau MedicalDRTS -0.07%27 Cash-to-Debt is 6.64 as of Jun. 2026, which is 37% below its 10-year median of 10.53. GuruFocus rates DRTS with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,396 Biotechnology companies, Alpha Tau Medical ranks worse than 50.64% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Alpha Tau Medical's cash to debt ratio for the quarter that ended in Jun. 2026 was 6.64.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Alpha Tau Medicalcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Alpha Tau Medical's Cash-to-Debt or its related term are showing as below:
DRTS'
s Cash-to-Debt Range Over the Past 10 Years
Min: 4.2 Med: 10.53 Max: No Debt
Current: 6.64
During the past 7 years, Alpha Tau Medical's highest Cash to Debt Ratio was No Debt. The lowest was 4.20. And the median was 10.53.
DRTS's Cash-to-Debt is ranked worse than 50.64% of 1396
companies
in the Biotechnology industry
Industry Median: 7.175
vs DRTS: 6.64
Alpha Tau Medical (NAS:DRTS) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Alpha Tau Medical Cash-to-Debt Related Terms
Alpha Tau Medical Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Alpha Tau Medical's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a Cash-to-Debt of 6.64 as of Jun. 2026. This is 37% below median its historical median of 10.53. Over the past decade, Alpha Tau Medical's Cash-to-Debt has ranged from 4.20 to 10,000.00. According to the industry distribution chart, Alpha Tau Medical ranks #707 out of 1396 companies in the Biotechnology industry, placing it in the top 50.6%.
Is Alpha Tau Medical's Cash-to-Debt too high?
Alpha Tau Medical's current Cash-to-Debt of 6.64 is 37% below median its 10-year median of 10.53. Over the past 10 years, this metric has ranged from a low of 4.20 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 7.18. Alpha Tau Medical's value of 6.64 is 7.5% below this industry median. Based on the distribution chart, Alpha Tau Medical ranks #707 out of 1396 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alpha Tau Medical has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Cash-to-Debt compare to OMER and ORIC?
According to the Biotechnology industry distribution chart, Alpha Tau Medical ranks #707 out of 1396 companies for Cash-to-Debt. This places Alpha Tau Medical in the lower half of its industry. The industry median Cash-to-Debt is 7.18. Alpha Tau Medical's value of 6.64 is 7.5% below this benchmark. Historically, Alpha Tau Medical's own Cash-to-Debt has ranged from 4.20 to 10,000.00 over the past decade. While the company's 10-year median is 10.53 vs. the industry median of 7.18, Alpha Tau Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.18, based on 1,396 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alpha Tau Medical's current Cash-to-Debt of 6.64 is 7.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alpha Tau Medical's current Cash-to-Debt is 6.64, which is 37% below median its own 10-year median of 10.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Cash-to-Debt of 6.64. The current Cash-to-Debt is 6.64, which is 37% below median its 10-year median of 10.53 and 7.5% below the Biotechnology industry median of 7.18. Alpha Tau Medical's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Cash-to-Debt is 6.64 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
27GF Score
Get the complete analysis for DRTS
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
